The two groups did not differ by age at acromegaly diagnosis, sex, BMI, GH, and IGF-I levels at acromegaly diagnosis, prevalence of hypopituitarism, prediabetes/diabetes mellitus, or central adrenal insufficiency, daily dose of hydrocortisone (or equivalent), prevalence of central hypogonadism or menopause, and class of drug for acromegaly treatment. This evidence concerns the gene IGF1 and hypopituitarism.